drugset
drugset / Trial / NCT05268003

A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia

NCT05268003 ↗

Phase 2 Terminated 4 enrolled M.D. Anderson Cancer Center
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The addition of ponatinib to mini-hyper-CVD chemotherapy and venetoclax will improve the complete remission rate in patients with relapsed or refractory T-cell acute lymphoblastic leukemia

Timeline

Start
2022-06-07
Primary completion
2026-04-21
Completion
2026-04-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Ponatinib Small molecule 45 mg Oral
Subject Venetoclax Small molecule 400 mg Oral

Indications

T-cell acute lymphoblastic leukemia